Charles Schwab Investment Management Inc. Grows Position in Schrödinger, Inc. (NASDAQ:SDGR)

Charles Schwab Investment Management Inc. raised its holdings in shares of Schrödinger, Inc. (NASDAQ:SDGR) by 2.2% during the 4th quarter, Holdings Channel.com reports. The firm owned 509,680 shares of the company’s stock after acquiring an additional 11,167 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Schrödinger were worth $9,832,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Avanza Fonder AB purchased a new stake in Schrödinger during the fourth quarter valued at about $577,000. Barclays PLC lifted its holdings in Schrödinger by 421.6% during the third quarter. Barclays PLC now owns 107,554 shares of the company’s stock valued at $1,995,000 after purchasing an additional 86,933 shares during the last quarter. State Street Corp lifted its holdings in Schrödinger by 1.8% during the third quarter. State Street Corp now owns 2,155,620 shares of the company’s stock valued at $39,987,000 after purchasing an additional 38,972 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. increased its position in shares of Schrödinger by 60.2% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,510,518 shares of the company’s stock valued at $67,718,000 after buying an additional 1,319,464 shares during the period. Finally, Rubric Capital Management LP increased its position in shares of Schrödinger by 17.7% during the third quarter. Rubric Capital Management LP now owns 3,685,503 shares of the company’s stock valued at $68,366,000 after buying an additional 555,503 shares during the period. 79.05% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Schrödinger news, CFO Geoffrey Craig Porges sold 5,491 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $21.76, for a total transaction of $119,484.16. Following the transaction, the chief financial officer now directly owns 27,544 shares in the company, valued at $599,357.44. This trade represents a 16.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 8.60% of the stock is owned by company insiders.

Schrödinger Trading Down 2.2 %

SDGR stock opened at $21.80 on Friday. The company’s 50 day moving average is $22.92 and its 200 day moving average is $20.77. The stock has a market cap of $1.59 billion, a price-to-earnings ratio of -9.32 and a beta of 1.62. Schrödinger, Inc. has a 1-year low of $16.67 and a 1-year high of $29.15.

Schrödinger (NASDAQ:SDGR) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.20). The company had revenue of $88.32 million during the quarter, compared to the consensus estimate of $83.20 million. Schrödinger had a negative return on equity of 35.77% and a negative net margin of 91.84%. As a group, sell-side analysts forecast that Schrödinger, Inc. will post -2.37 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

SDGR has been the topic of several analyst reports. Piper Sandler decreased their price target on Schrödinger from $50.00 to $45.00 and set an “overweight” rating on the stock in a research report on Thursday, February 27th. KeyCorp upped their price target on Schrödinger from $25.00 to $27.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Schrödinger has a consensus rating of “Buy” and a consensus target price of $32.29.

About Schrödinger

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.